An observational study in Hyperoxia, Hyperoxemia and Cerebrovascular Disorders, sponsored by Fatih Sultan Mehmet Training and Research Hospital. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by Fatih Sultan Mehmet Training and Research Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Hyperoxia with a site in Turkey — 2 open to participants now, 2 under way, none of them phase 3. Hyperoxia · Turkey.
Among the 19 studies in Hyperoxia with a site in Turkey, this one is one of 2 that started in 2026, is one of 8 observational ones, and was the 19th registered.
115 studies on the registry are indexed under Hyperoxia; 13 are open to participants now.
Browse Hyperoxia studies →2 of the 19 studies in Hyperoxia with a site in Turkey are open now. Recruiting first, the newest first:
Fatih Sultan Mehmet Training and Research Hospital · Sites in Turkey
Ages 18–65 · Healthy volunteers
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 7 Hyperoxia studies recruiting now, 3 set no upper age limit and 1 stops at 75 or younger; none take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 2 started in 2026.
This study's planned enrollment of 100 is close to the median of 104 across 32 observational studies indexed under Hyperoxia.
Median enrollment 60 across the 11 interventional studies, 60 across the 8 observational. Of the 17 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 19 has an industry lead sponsor. The 10 most frequent:
Fatih Sultan Mehmet Training and Research Hospital is the lead sponsor of 120 studies on the registry; 32 are open to participants now.
Fatih Sultan Mehmet Training and Research Hospital has 2 studies filed under Hyperoxia — fewer than ten, so there is no comparison to draw.
1 of the studies in Hyperoxia with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07859982Fatih Sultan Mehmet Training and Research HospitalHyperoxemia and Oxygen Reserve Index During Neurointerventional Anesthesia | 2027-04 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies in Hyperoxia with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to learn how often high blood oxygen levels (hyperoxemia) occur in adults receiving general anesthesia for planned (elective) neurointerventional procedures, such as brain aneurysm coiling or other catheter-based treatments of brain vessels. It will also look at how well a non-invasive finger sensor measurement called the Oxygen Reserve Index (ORi) reflects arterial oxygen levels.
The main questions it aims to answer are:
Participants will:
No extra blood samples will be taken for the study, and ORi values will not be used to guide care.
Background and rationale:
Oxygen is routinely given during general anesthesia to prevent hypoxemia. However, oxygen given beyond the patient's needs may cause arterial hyperoxemia, which has been linked to vasoconstriction, oxidative stress, and absorption atelectasis. Normobaric hyperoxia has been shown to reduce cerebral blood flow, and cumulative hyperoxemia exposure has been associated with unfavorable outcomes in ventilated patients with aneurysmal subarachnoid hemorrhage. Although these findings come from critically ill populations, they provide a physiological rationale for describing arterial oxygen levels in patients undergoing elective neurointerventional procedures, in whom maintaining cerebral perfusion is essential.
Standard pulse oximetry (SpO2) plateaus at high arterial oxygen levels and cannot detect hyperoxemia. The Oxygen Reserve Index (ORi) is a continuous, non-invasive, dimensionless index (0 to 1) derived from multi-wavelength pulse co-oximetry, reported to reflect oxygenation changes in the moderately hyperoxic range (approximately PaO2 100-200 mmHg). The ORi-PaO2 relationship varies across populations and clinical settings, and it has not been described in stable adults undergoing elective neurointerventional procedures under general anesthesia.
Study design:
This is a single-center, prospective, observational study conducted at the Department of Anesthesiology and Reanimation and the Interventional Radiology Unit of University of Health Sciences Fatih Sultan Mehmet Training and Research Hospital, Istanbul, Türkiye. No randomization, group allocation, or clinical intervention will be performed.
Procedures:
Anesthesia induction and maintenance, ventilator settings, FiO2, fluids, vasoactive drugs, and all other management will follow the attending anesthesiologist's routine practice. In addition to standard monitoring, an ORi-capable pulse co-oximetry sensor will be applied. ORi values will be recorded by the investigator but will not be used for clinical decision-making, and no changes in FiO2, ventilation, or treatment will be made based on ORi.
ORi, SpO2, FiO2, heart rate, mean arterial pressure, end-tidal carbon dioxide, body temperature, perfusion index, and signal quality will be recorded at the following time points: 5 minutes after intubation and initiation of mechanical ventilation (T1), 30 minutes (T2) and 60 minutes (T3) after the start of the procedure, every 60 minutes thereafter starting at 120 minutes if the procedure continues (T4 onward), and at the end of the procedure before FiO2 is increased for emergence (Tend).
Whenever an arterial blood gas sample is drawn by the clinical team for routine care, PaO2, PaCO2, pH, SaO2, hemoglobin, and lactate will be recorded and matched with ORi, SpO2, FiO2, perfusion index, and hemodynamic values recorded at the time of sampling or within 1 minute. No additional blood samples will be drawn for research purposes, and the timing and number of routine samples will not be altered.
Patients without a routine arterial blood gas will remain in the cohort for descriptive analyses; PaO2-based analyses will include all valid matched ORi-PaO2 pairs.
Sample size and statistical analysis:
Assuming an expected hyperoxemia proportion of 50%, a 95% confidence level, and a precision of +/-10%, the minimum required sample size is 96 patients; 100 patients will be enrolled to account for missing data. The proportion of matched measurements with PaO2 >=150 mmHg will be reported with 95% confidence intervals. Repeated measurements will be analyzed with mixed-effects models. The ORi-PaO2 relationship, including possible nonlinearity and plateau behavior, will be evaluated with appropriate regression models. The ability of ORi to discriminate PaO2 >=150 and >=200 mmHg will be explored with ROC analysis, accounting for within-patient clustering. A p value \<0.05 will be considered statistically significant.
Data protection:
All data will be de-identified, recorded on study case report forms, and used by the study team for scientific purposes only.
Adult patients (ASA I-III) scheduled for elective neurointerventional procedures under general anesthesia with routine invasive arterial monitoring at the Interventional Radiology Unit of University of Health Sciences Fatih Sultan Mehmet Training and Research Hospital, Istanbul, Türkiye. Eligible patients will be enrolled consecutively.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adult patients (ASA I-III) undergoing elective neurointerventional procedures under general anesthesia with routine invasive arterial pressure monitoring. All anesthetic, ventilatory, and oxygen management follows routine clinical practice. An ORi-capable pulse co-oximetry sensor is applied for observational recording only; ORi values are not used for clinical decisions. Routine monitoring data and results of arterial blood gas samples drawn for clinical care are recorded. No additional blood samples are taken for research purposes.
Other: Oxygen Reserve Index Monitoring (Observational)
Non-invasive ORi measurement via multi-wavelength pulse co-oximetry, recorded blinded to the anesthesia team and not used to guide care.
Proportion of Matched Arterial Blood Gas Measurements With PaO2 >=150 mmHg
Number of valid matched ORi-PaO2 measurement pairs with PaO2 \>=150 mmHg divided by the total number of valid matched pairs, multiplied by 100. Only arterial blood gas samples drawn for routine clinical care and matched to a valid ORi value recorded at the time of sampling or within 1 minute are included. Reported with 95% confidence interval.
Time frame: Intraoperative period, from intubation to the end of the procedure before FiO2 is increased for emergence (approximately 1-4 hours)
Proportion of Matched Arterial Blood Gas Measurements With PaO2 >=200 mmHg
Number of valid matched ORi-PaO2 pairs with PaO2 \>=200 mmHg divided by the total number of valid matched pairs, multiplied by 100, reported with 95% confidence interval.
Time frame: Intraoperative period, from intubation to the end of the procedure before FiO2 is increased for emergence (approximately 1-4 hours)
Proportion of Patients With at Least One PaO2 >=150 mmHg and >=200 mmHg Measurement
Percentage of patients with at least one valid matched arterial blood gas measurement showing PaO2 \>=150 mmHg, and separately \>=200 mmHg, among patients with at least one valid matched measurement.
Time frame: Intraoperative period, from intubation to the end of the procedure before FiO2 is increased for emergence (approximately 1-4 hours)
Per-Patient Proportion of Hyperoxemic Measurements
For each patient, the number of matched measurements with PaO2 \>=150 mmHg (and \>=200 mmHg) divided by that patient's total number of matched measurements, summarized across patients.
Time frame: Intraoperative period, from intubation to the end of the procedure before FiO2 is increased for emergence (approximately 1-4 hours)
Perioperative Changes in ORi, SpO2, FiO2, and Hemodynamic Parameters
ORi (dimensionless, 0-1), SpO2 (%), FiO2 (%), heart rate (beats/min), mean arterial pressure (mmHg), end-tidal CO2 (mmHg), body temperature (degrees C), and perfusion index recorded at T1 (5 min after intubation), T2 (30 min), T3 (60 min), every 60 min thereafter from 120 min, and Tend (end of procedure before FiO2 increase). Changes over time analyzed with mixed-effects models.
Time frame: Intraoperative period, from intubation to the end of the procedure before FiO2 is increased for emergence (approximately 1-4 hours)
Relationship Between ORi and PaO2
Association between ORi and PaO2 in matched measurement pairs, evaluated with linear and nonlinear regression models accounting for repeated measurements within patients, including assessment of a possible plateau in ORi at higher PaO2 values.
Time frame: Intraoperative period, from intubation to the end of the procedure before FiO2 is increased for emergence (approximately 1-4 hours)
Discriminative Ability of ORi for PaO2 >=150 mmHg and >=200 mmHg
Area under the receiver operating characteristic curve (AUROC) of ORi for detecting PaO2 \>=150 mmHg and \>=200 mmHg in matched pairs, with optimal cut-off, sensitivity, and specificity. Exploratory analysis accounting for within-patient clustering.
Time frame: Intraoperative period, from intubation to the end of the procedure before FiO2 is increased for emergence (approximately 1-4 hours)
Factors Associated With Hyperoxemia
Association of hyperoxemia (PaO2 \>=150 mmHg) with patient characteristics (age, sex, body mass index, ASA class, comorbidities), anesthesia characteristics (FiO2, anesthesia duration), and procedure characteristics (procedure type, duration, contrast volume), evaluated with multivariable mixed-effects models.
Time frame: Intraoperative period, from intubation to the end of the procedure before FiO2 is increased for emergence (approximately 1-4 hours)
Start is estimated for Oct 2026; primary completion for Apr 2027, 6 months later.
Of 16 observational studies under Hyperoxia, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 25. This study's planned 6 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fatih Sultan Mehmet Training and Research Hospital →